Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FMO5

FMO5

Basics

Aliases:
This biomarker is also known as:
  • dimethylaniline oxidase 5,
  • hepatic flavin-containing monooxygenase 5,
  • flavin containing monooxygenase 5,
  • Hepatic flavin-containing monooxygenase 5,
  • dimethylaniline monooxygenase [N-oxide-forming] 5,
  • FMO 5,
  • EC 1.14.13.8,
  • Dimethylaniline oxidase 5,

View in BioMuta

Description…

flavin containing monooxygenase 5

Attributes

QA State: Curated
Type: Gene
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

No additional prostate data available.

Performance Comment

19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html